LC
CORT icon

Lindbrook Capital’s Corcept Therapeutics CORT Stock Holding History

Lindbrook Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$26.2K Buy
229
+33
+17% +$2.01K ﹤0.01% 1244
2024
Q4 		$9.88K Hold
196
– – ﹤0.01% 1658
2024
Q3 		$9.07K Hold
196
– – ﹤0.01% 1722
2024
Q2 		$6.37K Buy
196
+80
+69% +$2.19K ﹤0.01% 1878
2024
Q1 		$2.92K Buy
116
+2
+2% +$47 ﹤0.01% 2111
2023
Q4 		$3.7K Hold
114
– – ﹤0.01% 2037
2023
Q3 		$3.11K Buy
114
+18
+19% +$521 ﹤0.01% 1968
2023
Q2 		$2.14K Sell
96
-84
-47% -$1.93K ﹤0.01% 2126
2023
Q1 		$3.9K Buy
180
+84
+88% +$1.84K ﹤0.01% 1959
2022
Q4 		$1.95K Sell
96
-244
-72% -$6.12K ﹤0.01% 2237
2022
Q3 		$9K Buy
340
+244
+254% +$6.53K ﹤0.01% 1362
2022
Q2 		$2K Hold
96
– – ﹤0.01% 1928
2022
Q1 		$2K Sell
96
-98
-51% -$2.08K ﹤0.01% 1968
2021
Q4 		$4K Buy
194
+42
+28% +$852 ﹤0.01% 1566
2021
Q3 		$3K Sell
152
-162
-52% -$3.39K ﹤0.01% 1391
2021
Q2 		$7K Buy
314
+78
+33% +$1.74K ﹤0.01% 1177
2021
Q1 		$6K Buy
236
+59
+33% +$1.57K ﹤0.01% 1196
2020
Q4 		$5K Buy
177
+81
+84% +$1.71K ﹤0.01% 1172
2020
Q3 		$2K Buy
96
+46
+92% +$733 ﹤0.01% 1372
2020
Q2 		$1K Hold
50
– – ﹤0.01% 1529
2020
Q1 		$1K Buy
+50
New +$619 ﹤0.01% 1420

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Lindbrook Capital's CORT Position: Q1 2025 in Review

Lindbrook Capital increased its Corcept Therapeutics (CORT) stake by 17% in Q1 2025, buying an estimated $2.01K and bringing the position to 229 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1244.

Lindbrook Capital first reported a position in CORT in Q1 2020 and has held it in 21 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Lindbrook Capital held 229 shares of Corcept Therapeutics worth $26.2K as of Q1 2025.
  • Lindbrook Capital bought 33 Corcept Therapeutics shares in Q1 2025, an estimated $2.01K.
  • Corcept Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1244 holding.
  • Lindbrook Capital first reported a position in Corcept Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.